25 years International Bladder Cancer Network (IBCN): The past, the present, and the future

Urol Oncol. 2023 Jul;41(7):302-306. doi: 10.1016/j.urolonc.2022.10.031. Epub 2022 Nov 25.

Abstract

In 1997 an international group of scientists organized a meeting in Barcelona, Spain, to discuss the use of biomarkers in the management of patients with bladder cancer. This meeting was the offspring of an - initially informal - group that finally resulted in the foundation and incorporation of the International Bladder Cancer Network (IBCN) e.V. in 2005. Over the years the group has supported several research initiatives and generated several recommendations on the use of biomarkers in the diagnosis and treatment of bladder cancer. Meeting quality was generated by inviting experts presenting state-of-the-art lectures or work in progress reports, interdisciplinarity and the limited number of participants supporting an open and personal exchange resulted in a format increasingly attracting participants from all over the world. The recent limitations caused by the Covid-19 pandemic were partially met by organizing several well attended webinars. The future challenge is to maintain the IBCN meeting spirit despite an increasing interest of the scientific community and industrial partners to participate. However, the integration of and interaction between increasingly more specialized disciplines is a challenge that can be better catalyzed by an international multidisciplinary network than mostly national professional associations.

Keywords: Bladder cancer; Diagnosis; International network; Molecular markers; Multidisciplinary; Therapy.

Publication types

  • Review

MeSH terms

  • Biomarkers
  • COVID-19*
  • Humans
  • Pandemics
  • Spain
  • Urinary Bladder Neoplasms* / diagnosis
  • Urinary Bladder Neoplasms* / therapy

Substances

  • Biomarkers